Metrics as of 10/14/2026, 08:43 PM (Berlin time), refresh in progress.
Apimeds Pharmaceuticals US Stock
Apimeds Pharmaceuticals US, Inc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Vinod Menon
- Employees
- 7
- Market cap
- $7 M
- IPO
- 09/05/2025
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Apimeds Pharmaceuticals US stock: price history
1D
-0.9%
1W
-35.0%
1M
+119.1%
6M
-75.6%
YTD
-72.1%
1Y
-74.6%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~28% weaker price swings than usual
Ask the agents about Apimeds Pharmaceuticals US
Apimeds Pharmaceuticals US stock metrics
P/E
-0.09
P/B
0.07
EV/EBITDA
-0.39
RETURN ON EQUITY
-19.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.14
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
37.3%
FLOAT SHARES
563,192
AVG. DAILY VOLUME (30D)
7,877,971
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Apimeds Pharmaceuticals US stock
What does Apimeds Pharmaceuticals US do?
Apimeds Pharmaceuticals US, Inc is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Vinod Menon, the company employs around 7 people.
The IPO was on 09/05/2025; the stock trades on AMEX under the ticker APUS.
When does Apimeds Pharmaceuticals US report next?
Around past earnings, price swings were roughly -28% stronger than usual.
Does Apimeds Pharmaceuticals US pay a dividend?
No, Apimeds Pharmaceuticals US currently does not pay a dividend.
Which stocks are comparable to Apimeds Pharmaceuticals US?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Apimeds Pharmaceuticals US stock analyzed?
Clicking "Analyze stock" lets five strategies assess Apimeds Pharmaceuticals US against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.